» Articles » PMID: 23671440

The Role of Counselling and Other Factors in Compliance of Postmenopausal Osteoporotic Patients to Alendronate 70 Therapy

Overview
Journal Arch Med Sci
Specialty General Medicine
Date 2013 May 15
PMID 23671440
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: The aim of the study was to assess the role of patient counselling, nurse assistance and effects of biochemical examinations in adherence of women with postmenopausal osteoporosis to alendronate 70 administration over 12 months of therapy.

Material And Methods: Compliance and persistence to alendronate 70 therapy were assessed in a prospective study of 123 postmenopausal women, followed up for one year. The patients were divided into 4 groups (controls, counselled group, biochemical group and nurse assisted group) with monitoring every 6 months; in the nurse assisted group, additional phone contacts were made after 3 and 9 months of treatment. After 12 months, compliance and persistence were analysed. The medication possession ratio (MPR) was regarded as optimal when its value exceeded 80%.

Results: The compliance to alendronate 70 therapy was 54.03% in the control group and the mean persistence with medication was 197 days. The MPR above 80% was observed in 37.5%, and, after 1 year, 43.75% of patients were found persistent with the therapy. In the remaining groups, both compliance and persistence were higher but not statistically significantly, compared to the control group. Neither patient's age, education, diet, nor physical activity influenced the compliance with prescribed therapy. The most common reason to discontinue therapy was either its side effects or smoking.

Conclusions: The obtained results suggest that better adherence with medical recommendations is observed in patients who receive additional attention, e.g. counselling, biochemical tests or nursing care. The critical elements for therapy discontinuation were side effects and smoking.

Citing Articles

Knowledge and compliance towards alendronate therapy among postmenopausal women with osteoporosis in Palestine.

Radwan A, Shraim N, Elaraj J, Hamad A, Fatayer D, Jarar B BMC Womens Health. 2022; 22(1):105.

PMID: 35392893 PMC: 8991824. DOI: 10.1186/s12905-022-01690-5.


Influence of General Mineral Condition on Collagen-Guided Alveolar Crest Augmentation.

Kozakiewicz M, Szymor P, Wach T Materials (Basel). 2020; 13(16).

PMID: 32824644 PMC: 7476019. DOI: 10.3390/ma13163649.


Improving drug adherence in osteoporosis: an update on more recent studies.

Jaleel A, Saag K, Danila M Ther Adv Musculoskelet Dis. 2018; 10(7):141-149.

PMID: 30023009 PMC: 6047244. DOI: 10.1177/1759720X18785539.


General self-efficacy level and health behaviours in women over the age of 45 years who have undergone osteoporosis treatment.

Janiszewska M, Kulik T, Zolnierczuk-Kieliszek D, Drop B, Firlej E, Gajewska I Prz Menopauzalny. 2018; 16(3):86-95.

PMID: 29507574 PMC: 5834921. DOI: 10.5114/pm.2017.70584.


Evaluation of a "Just-in-Time" Nurse Consultation on Bone Health: A Pilot Randomized Controlled Trial.

Roblin D, Zelman D, Plummer S, Robinson B, Lou Y, Edmonds S Perm J. 2017; 21:16-112.

PMID: 28746019 PMC: 5528825. DOI: 10.7812/TPP/16-112.


References
1.
Ringe J, Christodoulakos G, Mellstrom D, Petto H, Nickelsen T, Marin F . Patient compliance with alendronate, risedronate and raloxifene for the treatment of osteoporosis in postmenopausal women. Curr Med Res Opin. 2007; 23(11):2677-87. DOI: 10.1185/03007x226357. View

2.
Curtis J, Westfall A, Cheng H, Lyles K, Saag K, Delzell E . Benefit of adherence with bisphosphonates depends on age and fracture type: results from an analysis of 101,038 new bisphosphonate users. J Bone Miner Res. 2008; 23(9):1435-41. PMC: 2574615. DOI: 10.1359/jbmr.080418. View

3.
Cramer J, Lynch N, Gaudin A, Walker M, Cowell W . The effect of dosing frequency on compliance and persistence with bisphosphonate therapy in postmenopausal women: a comparison of studies in the United States, the United Kingdom, and France. Clin Ther. 2006; 28(10):1686-94. DOI: 10.1016/j.clinthera.2006.10.013. View

4.
Cramer J, Gold D, Silverman S, Lewiecki E . A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporos Int. 2007; 18(8):1023-31. DOI: 10.1007/s00198-006-0322-8. View

5.
Papaioannou A, Ioannidis G, Adachi J, Sebaldt R, Ferko N, Puglia M . Adherence to bisphosphonates and hormone replacement therapy in a tertiary care setting of patients in the CANDOO database. Osteoporos Int. 2003; 14(10):808-13. DOI: 10.1007/s00198-003-1431-2. View